MannKind Corporation has completed patient randomization in its Phase 1b INFLO-1 study and enrolled the first patient in the global Phase 2 INFLO-2 trial for nintedanib DPI, an inhaled therapy for idiopathic pulmonary fibrosis (IPF). The Phase 1b data, expected in Q3 2026, will assess safety and tolerability, while the Phase 2 study aims to evaluate efficacy and optimal dosing in about 210 patients worldwide. This inhaled form of nintedanib targets lung delivery to reduce systemic side effects compared to oral therapy, potentially improving patient adherence and enabling combination treatments. These milestones mark significant progress in developing a more convenient and potentially better-tolerated IPF treatment.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
The global hybrid robots market is projected to grow from $5.68 billion in 2026 to $10.03 billion by 2030, with a CAGR of 15.3%. Growth is fueled by advances in AI, autonomous operations, and smart manufacturing, alongside rising demand for robots in...
